Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before...

FDA - GMP

PolyCrystalLine SpA has been inspected by FDA and received the GMP certification from AIFA for the physico-chemical analyses. For any request please contact us soon....

Meet us at CPhI Worldwide - Madrid 2018

We invite you to join us at our stand #3C62 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact marco.glucini@polycrystalline.it...

MyCrystalPro: Our Online Portal

Polycrystalline can be entrusted with your most sensitive projects for method development and validation of API’s intermediates, raw materials and finished products.

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intell...

REGISTRATION NOW OPEN! - 10th ED. CF@BO 2019

Registration Now Open CF@Bo n.10 is dedicated to Professor Joel Bernstein  (12/9/1941 -  2/1/2019) ABOUT THE CONVENTION The investigation and optimization of crystal forms are at the forefront of industrial as well as fundamental research. The event will bring together acad...

Controlled Substances Studies & Analysis

PolyCrystalLine received the authorization N°101/2017 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for client...

Meet us at DCAT in New York!

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it....

Meet us at DCAT in New York!

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it....

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project&rdquo...

Highly Potent API

Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients wit...

FRENCH CERTIFICATION

  PolyCrystalLine s.r.l. received the approval from French Health Ministry as a CRO for R&D activities, the French companies who use our services can benefit of a tax credit in compliance with the article 244 quater B of the French general code of taxes. (see the PDF attached)  ...

Minodronic Acid novel form

PolyCrystalLine discovered a novel crystalline form of Minodronic Acid and filed a patent application. For additional information contact info@polycrystalline.it...

Sostanze Altamente Attive: Rischi E Contenimento

Polycrystalline, CSV Life Science e Pharma-Hub organizzano la Giornata di Studio sul tema "SOSTANZE ALTAMENTE ATTIVE: RISCHI E CONTENIMENTO" che si terrà a Formia il giorno 05 Aprile 2018.   Sedi delle giornate di studio Formia 1ª edizione 05 Aprile 2018 - Kora Park Hotel, Via ...